AVIR Stock — Atea Pharmaceuticals Inc.: Cash, EV, Pipeline

What they do

We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases.

Source: 10-K FY2025 via SEC EDGAR

Share price

$4.31

Market cap

$345.7M

Cash

$219.5M

Enterprise value

$126.2M

Balance sheet

Cash	$219.5M
Debt	$0.0M
Net cash	$219.5M
Enterprise value	$126.2M
Basic shares	80.2M shares
Fully diluted shares	108.8M shares
Fully diluted market cap	$468.9M
Cash per share	$2.74
Quarterly burn	$37.1M
Cash runway	5.9 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

80.2M

Pre-funded warrants

0.0M

Options

21.9M

RSUs

2.6M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

4.1M

FDSO

108.8M

Cap table as of 2026-06-30.

Price history

Loading AVIR daily closes…

Loading price history…

Next catalyst

Bemnifosbuvir-Ruzasvir · Jan 12 - Feb 23 in 9 wks · Phase 3 · HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 9 wks	Bemnifosbuvir-Ruzasvir	Phase 3	HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection	early Q1 2027
Jan 12 - Feb 23 in 9 wks	AT-587	Phase 1	Hepatitis E	—
GUIDEDEst. May 16, 2027 in 5 mo quarter midpoint	bemnifosbuvir + ruzasvir (BEM/RZR) NDA submission to FDA	Not disclosed	to FDA	Q2 2027

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

BEM/RZR (bemnifosbuvir + ruzasvir)

Phase 3 · Active Modality: oral antiviral

Target NS5B/NS5A

Partnerships Merck (MSD International GmbH): worldwide exclusive license for ruzasvir (Dec 2021); milestones (incl. $5M on first C-BEYOND patient, Apr 2025) + tiered royalties high single digits to mid-teens

Indications

Hepatitis C virus (HCV) (Phase 3)

Catalysts

— early first quarter 2027
— second quarter 2027

Status note Lead program: fixed-dose combination for HCV. C-BEYOND (US/Canada) reported topline July 2026; C-FORWARD (ex-North America, ~120 sites/17 countries) completed enrollment June 2026; NDA submission targeted second quarter 2027 (pending positive C-FORWARD data).

AT-587

Phase 1 · Active Modality: oral antiviral

Target RdRp

Indications

Hepatitis E virus (HEV) (Phase 1)

Status note Potential first direct-acting antiviral for HEV, focused on chronic HEV in immunocompromised patients. Phase 1 first-in-human trial in healthy volunteers initiated July 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Bemnifosbuvir-Ruzasvir
Lead indication	HEPATITIS C VIRUS CHRONIC INFECTION
Lead phase	Phase 3
Active trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07037277	Phase 3	Active, not recruiting	Sponsor	AVIR	—	HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection	early Q1 2027
NCT06868264	Phase 3	Active, not recruiting	Sponsor	AVIR	—	HEPATITIS C VIRUS CHRONIC INFECTION	—
NCT07728487	Phase 1	Recruiting	Sponsor	AVIR	—	Hepatitis E	—
NCT07314346	Phase 1	Recruiting	Sponsor	AVIR	—	Healthy Volunteer Study	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 4 active trials for Atea Pharmaceuticals, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Tang Capital Partners	4,814,700	no change	1.02%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

AVIR — Atea Pharmaceuticals Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

AVIR — Atea Pharmaceuticals Inc.